These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 39167797)

  • 61. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune checkpoints in the tumor microenvironment.
    Toor SM; Sasidharan Nair V; Decock J; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Establishment of immune suppression by cancer cells in the tumor microenvironment.
    Nishikawa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(2):114-122. PubMed ID: 38346752
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tumor immune microenvironment-based clusters in predicting prognosis and guiding immunotherapy in breast cancer.
    Liu Y; He X; Yang YI
    J Biosci; 2024; 49():. PubMed ID: 38287674
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cuproptosis depicts tumor microenvironment phenotypes and predicts precision immunotherapy and prognosis in bladder carcinoma.
    Li H; Zu X; Hu J; Xiao Z; Cai Z; Gao N; Chen J
    Front Immunol; 2022; 13():964393. PubMed ID: 36211344
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors.
    Gil-Jimenez A; van Dijk N; Vos JL; Lubeck Y; van Montfoort ML; Peters D; Hooijberg E; Broeks A; Zuur CL; van Rhijn BWG; Vis DJ; van der Heijden MS; Wessels LFA
    Nat Commun; 2024 Mar; 15(1):2538. PubMed ID: 38514623
    [TBL] [Abstract][Full Text] [Related]  

  • 70. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
    Saleh R; Elkord E
    Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
    Giannone G; Ghisoni E; Genta S; Scotto G; Tuninetti V; Turinetto M; Valabrega G
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575899
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
    Uche IK; Kousoulas KG; Rider PJF
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
    Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
    Front Immunol; 2022; 13():956224. PubMed ID: 36032075
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cancer therapy with immune checkpoint inhibitor and CSF-1 blockade: A mathematical model.
    Siewe N; Friedman A
    J Theor Biol; 2023 Jan; 556():111297. PubMed ID: 36228716
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies.
    Huang M; Cha Z; Liu R; Lin M; Gafoor NA; Kong T; Ge F; Chen W
    Front Immunol; 2024; 15():1399926. PubMed ID: 38817608
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improvement of STING-mediated cancer immunotherapy using immune checkpoint inhibitors as a game-changer.
    Lee SE; Jang GY; Lee JW; Park SH; Han HD; Park YM; Kang TH
    Cancer Immunol Immunother; 2022 Dec; 71(12):3029-3042. PubMed ID: 35610387
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy.
    Srivastava A; Rathore S; Munshi A; Ramesh R
    AAPS J; 2021 Feb; 23(2):30. PubMed ID: 33586060
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer.
    Chen Y; Sun J; Luo Y; Liu J; Wang X; Feng R; Huang J; Du H; Li Q; Tan J; Ren G; Wang X; Li H
    J Transl Med; 2022 Dec; 20(1):615. PubMed ID: 36564797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.